TEVA Teva Pharmaceutical Industries Ltd.: רווח למניה בשנים עשר החודשים האחרונים

Teva Pharmaceutical Industries (TEVA) is systematically reducing harmful emissions, leveraging its extensive presence in the US, where the company produces every tenth prescription drug. The current YoY ttm net income per share growth on GURU.Markets shows that the latest figure is -28.50. This trend is supported by strategic licenses with biotech startups for the joint production of complex biosimilars.
Teva Pharmaceutical Industries Ltd. - פילוחים אנליטיים ומדדי מפתח (TEVA)

Analyzing earnings per share (EPS) dynamics is critical for separating fundamental stability from market noise. This metric measures the annual growth rate of net income (TTM), allowing for an assessment of real capital generation efficiency. By analyzing the EPS YoY TTM shift, an investor can determine the rate of change in the asset's yield. For Teva Pharmaceutical Industries (TEVA), the stability of these values is supported by a global network of plants that ensures operational flexibility.